MENUMENU
  • Covid Clear
  • About Us
        • About Us

          An industry leading services provider in viral challenge studies and laboratory services supporting product development for customers developing antivirals, vaccines and respiratory therapeutics.

          • More about hVIVO
        • Overview
        • Executive Leadership Team
        • Scientific Papers / Abstracts
        • Quality Commitment
        • Ethics & Compliance
        • FluCamp
        • Human Challenge Programme
        • Challenge Agent Manufacturing
        • PrEP Biopharm Ltd
        • Imutex Ltd.
  • Services
        • Human challenge full-service solution
        • human challenge full service solution

          Industry leading provider of viral challenge studies

          • See Our Solution
        • hVIVO Challenge Models
          • Influenza
          • RSV
          • HRV
          • Asthma
          • COPD
          • Cough
        • Laboratory Services
          • Virology
          • Immunology
          • Biomarkers
  • News, Media & Events
        • News, Media & Events

          A source for the latest press releases, scientific publications and other media as well as details of investor and scientific events that we attend and host across the world.

        • News & Media
        • Media Coverage
        • Company News
        • Media Press Kit
        • Videos
        • Events
        • img

          LATEST PRESS RELEASE

          21.01.21 Article published in Drug Discovery Today
        • UPCOMING EVENTS

          Shares Investor Webinar

          Wednesday 3rd February

  • Volunteers
  • Careers
  • Contact Us

Categories for Scientific Papers

ERS International Congress 2020 Presentation: Experimental Respiratory Syncytial Virus Infection in Adults 60-75 years

Temporal relationships of cytokines, chemokines and cellular biomarkers during Human Rhinovirus (HRV) infection in asthmatics

A Key Endpoint in Viral Challenge Models of Asthma Exacerbations

Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human influenza challenge model

DEVELOPMENT AND VALIDATION OF AN ALGORITHM PROGNOSTIC FOR INFLUENZA CONTAGIOUSNESS

THE HUMAN VIRAL CHALLENGE MODEL WITH A/PERTH/16/2009 H3N2A SYSTEMATIC ANALYSIS FROM FIVE CLINICAL STUDIES

Scientific Paper 106 – Effect of pre-existing serum and mucosal antibody on experimental respiratory syncytial virus (RSV) challenge and infection of adults

Scientific paper 49 – An oseltamivir treatment-selected influenza A/N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo

Scientific paper 48 – Influenza virus infection in the second and third trimesters of pregnancy : a clinical and seroepidemiological study

Scientific paper 45 – Targeting influenza virus neuraminidase—a new strategy for antiviral therapy

1 2 3 … 10 Next »
1 2 3 … 10 Next »

Whether you’re a potential customer, job seeker, health professional or an investor, you can find the best way to contact us from the list below.

Contact Us
  • Terms & Conditions
  • Careers
  • Sitemap
© 2021 Copyright hVIVO Services Limited. All rights reserved. hVIVO Services Limited (“hVIVO”) is registered in England and Wales with registration number 02326557 and registered office at Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX, UK.
Privacy Policy | Cookie Policy